Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 145Kidney Neoplasms 42Neoplasms 39Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 31Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Carcinoma 10Stomach Neoplasms 8Neuroendocrine Tumors 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Adenoma, Islet Cell 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Clear-cell metastatic renal cell carcinoma 6

Interventions

Paclitaxel 3Bevacizumab 3fludarabine 2Nivolumab 2Gemcitabine 2Carboplatin 2rucaparib 1pembrolizumab 1liposomal doxorubicin 1dostarlimab 1Taxes 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Melphalan 1Ipilimumab 1Immunoglobulin G 1Erlotinib Hydrochloride 1Doxorubicin 1Docetaxel 1Disulfides 1Dexamethasone 1Celecoxib 1Capecitabine 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Sunitinib × Clear all
NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Cathay General Hospital

Phase 2 Completed
30 enrolled
Gynecologic

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡